Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tavlesse

- PMLiVE

NICE set to reject Kyowa Kirin’s Crysvita for XLH

Committee says the rare disease therapy isn’t value for money

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Keytruda cleared for frontline lung cancer in England – but only after another pricing deal

Keytruda first drug to exit Cancer Drugs Fund and go through Budget Impact Test

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

- PMLiVE

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

News from the frontline of healthcare, pharma and biotech

- PMLiVE

Keytruda gains NICE clearance in first line bladder cancer

MSD extends advantage in immunotherapy with Cancer Drugs Fund clearance

Sanofi reception

NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

Dupixent is still too expensive despite discount, says the UK’s cost effectiveness body

- PMLiVE

NICE says OK to Keytruda for bladder cancer via the CDF

Becomes the first immunotherapy recommended for UC after chemotherapy

- PMLiVE

Merck and Pfizer set to win NICE backing for Bavencio

The PD-L1 inhibitor is being assessed for the treatment of mMCC patients

EISAI

NICE reverses its rejection of Eisai’s Lenvima

The cost-effectiveness watchdog has now backed the thyroid cancer treatment

Roche Basel Switzerland

NICE backs Roche’s Gazyvaro after initial rejection

An undisclosed discount swayed the cost-effectiveness body

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links